[HTML][HTML] Targeting menin for precision therapy in high-risk acute myeloid leukemia

A Jamil, Z Qureshi, ZM El-Amir… - Leukemia Research …, 2024 - Elsevier
Objective This mini-review provides an overview of the current evidence for Revumenib, a
first-in-class menin inhibitor, in treating AML with KMT2A rearrangements or NPM1 …